PT  - JOURNAL ARTICLE
AU  - Alyssa Bilinski
AU  - Joshua A. Salomon
AU  - John Giardina
AU  - Andrea Ciaranello
AU  - Meagan C. Fitzpatrick
TI  - Passing the Test: A Model-based analysis of safe school-reopening strategies
AID  - 10.1101/2021.01.27.21250388
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.01.27.21250388
4099  - http://medrxiv.org/content/early/2021/01/29/2021.01.27.21250388.short
4100  - http://medrxiv.org/content/early/2021/01/29/2021.01.27.21250388.full
AB  - Background The COVID-19 pandemic has induced historic educational disruptions. In December 2020, at least two-thirds of US public school students were not attending full-time in-person education. The Biden Administration has expressed that reopening schools is a priority.Objective To compare risks of SARS-COV-2 transmission in schools across different school-based prevention strategies and levels of community transmission.Design We developed an agent-based network model to simulate transmission in elementary and high school communities, including home, school, and inter-household interactions.Setting We parameterized school structure based on average US classrooms, with elementary schools of 638 students and high schools of 1,451 students. We varied daily community incidence from 1 to 100 cases per 100,000 population.Patients (or Participants) We simulated students, faculty/staff, and adult household members.Interventions We evaluated isolation of symptomatic individuals, quarantine of an infected individual’s contacts, reduced class sizes, alternative schedules, staff vaccination, and weekly asymptomatic screening.Measurements We projected transmission among students, staff and families during one month following introduction of a single infection into a school. We also calculated the number of infections expected for a typical 8-week quarter, contingent on community incidence rate.Results School transmission risk varies according to student age and community incidence and is substantially reduced with effective, consistent mitigation measures. Nevertheless, when transmission occurs, it may be difficult to detect without regular, frequent testing due to the subclinical nature of most infections in children. Teacher vaccination can reduce transmission to staff, while asymptomatic screening both improves understanding of local circumstances and reduces transmission, facilitating five-day schedules at full classroom capacity.Limitations There is uncertainty about susceptibility and infectiousness of children and low precision regarding the effectiveness of specific prevention measures, particularly with emergence of new variants.Conclusion With controlled community transmission and moderate school-based prevention measures, elementary schools can open with few in-school transmissions, while high schools require more intensive mitigation. Asymptomatic screening should be a key component of school reopenings, allowing reopening at higher community incidence while still minimizing transmission risk.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors were supported by the Centers for Disease Control and Prevention though the Council of State and Territorial Epidemiologists (NU38OT000297-02; AB, JAS), the National Institute of Allergy and Infectious Diseases (R37AI058736-16S1; ALC and K01AI141576; MCF), the National Institute on Drug Abuse (3R37DA01561217S1; JAS). The papers' contents are solely the responsibility of the authors and do not necessarily represent the official views of the fundersAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesModel code is available at https://github.com/abilinski/BackToSchool2. https://github.com/abilinski/BackToSchool2